PDF   Print   View All
November 04, 2002
Hemispherx Biopharma RNA Drug Technology Targets New Molecular Defects Uncovered in Prostate Cancer
National Human Genome Research Pinpoints First Specific Gene Which Confers High Risk for Prostate Cancer

Prostate 'Cancer Susceptibility Gene' is New Therapeutic Target


Philadelphia, PA, Monday, November 04, 2002: -- Hemispherx Biopharma, Inc. (Amex: HEB) reported today that its RNA-based drug technology has immediate potential as the first specific therapy for a new genetically based prostate cancer pinpointed by the National Human Genome Research Institute, National Institutes of Health (NIH). Collaborating institutions, including more than 15 academic medical centers in the U.S. and Europe, reported on patients with prostate cancer and their family members. A recent Nature scientific journal expands on these findings.
Background
Although prostate cancer is the most common non-cutaneous malignancy diagnosed in men in the United States, very little has been known about inherited factors that influence its genetic disposition. Much better knowledge exists, for example, regarding causes of breast and ovarian cancers. The aggressive form of prostate cancer kills more than 30,000 Americans per year.
New Diagnostic Finding and Therapeutic Implications for RNA-based Drugs
NIH said (Nature Genetics, vol. 30, 2002) that hereditary prostate cancer is associated with a critical new defect in a mediator (e.g. bodily defense) substance called "RNase L". RNase L is a natural antiviral material commonly activated by exposure of the body to certain types of RNA (ribonucleic acid), called ds (double-stranded) RNA. DsRNA usually appears when viruses begin multiplying in the human body as part of the general immune response alarm signal to ward off infection. A high percentage of prostate cancer cases demonstrated the defect in the RNase L alarm signal. In contrast, no defects were seen in 698 control (or normal) individuals, of which 284 controls were African Americans, a group predisposed to prostate cancer. The NIH study concludes "these findings on ... germline mutations in this gene [RNase L] could lead to early diagnosis and therapeutic approaches for prostate cancer ... ."
Prostate Cancer Spread
Data presented in follow-on studies at the University of Michigan indicate that, as the prostate cancer spreads, or metastasizes, up to 55 growth controlling genes are turned on and render an even deadlier form of the disease. Thus, it appears potentially very important to identify, and correct if possible, the underlying initial gene defect - RNase L - as quickly as possible.
Present State of Prostate Cancer Therapy and Prevention
Present prostate cancer therapy is not based on specific genetic alterations that lead to the cancer. Therapeutic success is often limited in magnitude, significant side effects are observed, and benefits are generally of short duration. Similarly, prevention is limited to general dietary measures which may increase overall dietary quality (including dietary supplementation in anti-carcinogenic food products) but without any specificity for protecting the prostate gland.
Present State of RNA-directed Immune Defense Mediators in Human Disease
Hemispherx has evolved as a world leader in creating new experimental drug modalities which may operate at the RNase L level. This technology is protected by nearly 400 patents worldwide. In addition, Hemispherx is presently conducting Phase III Clinical Studies in Chronic Fatigue Syndrome and Phase IIb studies in HIV/AIDS. These diseases were selected for clinical development because of the dysfunction in RNase L. Company scientists reasoned that these defects might create a favorable environment for the development of chronic viral infection and therefore needed to be corrected to achieve potential therapeutic outcomes. The Company has also conducted studies in Hepatitis B, another chronic viral infection associated with RNase L antiviral/immunodefense abnormalities. The new clinical studies, prostate studies, in individuals with prostate cancer and /or at high risk to its development, suggest that this same immunological pathway, when unbalanced, may also create a favorable environment for the development of prostate cancer.
About Hemispherx
Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company's Web site at www.hemispherx.net.


Contact(s):
Hemispherx Biopharma, Inc., Investor Relations
(215) 988-1712, Fax: (215) 988-1554

Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223

Robert Giordano, MRB Institutional Investors, MRB
(212) 495-0200, Fax: (212) 495-0746

HEB's Web Site: www.hemispherx.net


Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results including financial results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.